NeuroSense Therapeutics Ltd (NRSN): Next-Year EPS Estimate 37.77%
As of 2026-04-01, NeuroSense Therapeutics Ltd (NRSN) has a next-year EPS growth estimate of 37.77%.
Analyst estimates for NRSN have remained steady in the most recent observable window, with next-year EPS growth projected at 37.77%.
Current Snapshot
- Sector
- Healthcare
- Industry
- Biotechnology
- EPS growth next year
- 37.77%
- EPS growth this year
- N/A
- EPS next quarter (est)
- N/A
- Last price
- $0.76
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-04-01 | 37.77% | N/A | N/A | $0.76 |
| 2026-04-01 | 37.77% | N/A | N/A | $0.75 |
| 2026-04-01 | 37.77% | N/A | N/A | $0.76 |
| 2026-04-01 | 37.77% | N/A | N/A | $0.76 |
| 2026-03-31 | 37.77% | N/A | N/A | $0.75 |
| 2026-03-31 | 37.77% | N/A | N/A | $0.75 |
Recent News
Screen Performance
Aggregate stats across all 1761 tickers our top-EPS-revision screen has flagged over the past 64 days.
- Median return since detection
- +5.1%
- % of tickers in the green
- 62%
- Median return on winners
- +17.5%
- Large revisions captured
- 746
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Frequently Asked Questions
What is NeuroSense Therapeutics Ltd's next-year EPS growth estimate?▾
As of 2026-04-01, NeuroSense Therapeutics Ltd (NRSN) has a next-year EPS growth estimate of 37.77%, based on analyst consensus.
What sector and industry does NeuroSense Therapeutics Ltd belong to?▾
NeuroSense Therapeutics Ltd operates in the Healthcare sector, specifically the Biotechnology industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. NRSN appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. NeuroSense Therapeutics Ltd (NRSN) appears here because it was detected by our daily top-EPS-revision-performer screen.
← All reports